Cancer Diagnostics Market to Register Remarkable Growth of USD 28.21 Billion by 2029 with Analysis of Size, Share, Opportunities, Growth Prospectus and Upcoming Trends – QNT Press Release


NEW YORK, Aug. 11, 2022 /PRNewswire/ — According to a Comprehensive Research Report by Data Bridge Market Research on Global Cancer Diagnostics Market research report is an expert’s analysis which mainly includes companies, types, applications, regions, countries, etc. Also the reports give analysis on sales, revenue, trade, competition, and investment, forecast. Cancer Diagnostics market research covers impacts on the upstream, midstream and downstream industries. Also, this study offers a detailed market estimates by emphasizing statistics on several aspects covers market dynamics like drivers, barriers, opportunities, threats, and industry news & trends. Global Cancer Diagnostics Market report has been prepared by keeping in mind the customer requirements which assist them in increasing their return on investment (ROI). Furthermore, it endows with historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Cancer diagnostics market report also evaluates the market status, market share, current trends, growth rate, future trends, market drive rs, opportunities, challenges, risks, entry barriers, sales channels, and distributors.

Data Bridge Market Research analyses that the cancer diagnostics market is expected to reach the value of USD 28.21 billion by the year 2029, at a CAGR of 7.29% during the forecast period. The rise in the Cancer cases provides growth opportunities to the market.

Grab Sample Report with Complete Graphs, Charts and Figures @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-diagnostics-market&PNW/10Aug2022

Cancer has a significant impact on society all over the world. It is one of the leading causes of death worldwide, with a higher prevalence in developed and emerging markets. The alarming rate of rising cancer prevalence compels healthcare providers to reconsider cancer treatment goals and shift their focus to prevention. Cancer diagnostics that are not only specific and sensitive, but also capable of detecting cancer in its early stages would be required.

Cancer diagnostics is the process of detecting various biomarkers, proteins, and symptoms that lead to the presence of a cancerous tumour in patients. The detection of specific biomarkers and proteins that are common in cancer disorders leads to the diagnosis process. The process of detecting cancer includes the use of specific technology and devices used in its diagnosis.

List of Companies Profiled in the Cancer Diagnostics Market Reports are:

  • Abbott. (US)
  • DiagnoCure Inc. (Canada)
  • Thermo Fisher Scientific Inc. (US)
  • Illumina, Inc. (US)
  • QIAGEN (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Agilent Technologies, Inc. (US)
  • Quest Diagnostics Incorporated. (US)
  • Merck KGaA, (Germany)
  • Hologic, Inc. (US)
  • BD. (US)
  • GlaxoSmithKline plc. (UK)
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb Company (US)
  • Eli Lilly and Company (US)
  • Pfizer, Inc. (US)
  • Genomic Health, Inc. (US)
  • bioMérieux SA (France)
  • Astellas Pharma Inc. (Japan)
  • Myriad Genetics, Inc. (US)

Opportunities for New Entrants:-

Increasing personalised medicine, mass cytometry development, and the combination of cell- and bead-based flow cytometry technologies, improving healthcare infrastructure in emerging markets, and the rise of miniaturised and technologically advanced devices will all create new opportunities for the cancer diagnostics market.

Access Full 350 Page PDF Research Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-cancer-diagnostics-market?PNW/10Aug2022

Recent Development

Siemens Healthineers will launch Magnetom Free in November 2021. Star is a low-cost whole-body MRI scanner that is intended to improve global access to magnetic resonance imaging.

Agilent Technologies Inc. announced in October 2021 that its PD-L1 IHC 22C3 pharmDx assay has been labelled for use in Triple-Negative Breast Cancer (TNBC) in the European Union.

The report provides insights on the following pointers:

  1. Market Penetration: Comprehensive information on the product portfolios of the top players in the Cancer Diagnostics market.
  2. Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.
  3. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.
  4. Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.
  5. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Cancer Diagnostics market.

Market Segmentation:-

By Type

(Imaging Testing, Biomarkers…

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center